Literature DB >> 33713427

Venetoclax induces profound and sustained responses in patients with relapsed/refractory light-chain amyloidosis.

Hélène Pasquer1, Karim Belhadj1, Jehan Dupuis1, Sylvia Oghina2,3, Antoine Galat3, Amandine Ladaique4, Alizée Maarek1, Louise Roulin1, Romain Gounot1, Elsa Poulot5, Asma Beldi-Ferchiou6, Valérie Molinier-Frenkel6, Corinne Haioun1,2, Thibaud Damy2,3, Fabien Le Bras1, François Lemonnier1,2.   

Abstract

Entities:  

Keywords:  AL amyloidosis; BH3 mimetics; apoptosis; cardiac amyloidosis; venetoclax

Year:  2021        PMID: 33713427     DOI: 10.1111/bjh.17380

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  2 in total

Review 1.  AL Amyloidosis: Current Chemotherapy and Immune Therapy Treatment Strategies: JACC: CardioOncology State-of-the-Art Review.

Authors:  Giada Bianchi; Yifei Zhang; Raymond L Comenzo
Journal:  JACC CardioOncol       Date:  2021-10-19

2.  [Efficacy and safety analysis of BCL-2 inhibitor in relapsed/refractory multiple myeloma with t (11;14) in a single center].

Authors:  J Y Bi; L Wen; W B Duan; Y Liu; S S Wang; X J Huang; J Lu
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2022-02-14
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.